TY - JOUR
T1 - Developing a framework to incorporate real-world evidence in cancer drug funding decisions
T2 - The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
AU - Chan, Kelvin
AU - Nam, Seungree
AU - Evans, Bill
AU - Deoliveira, Claire
AU - Chambers, Alexandra
AU - Gavura, Scott
AU - Hoch, Jeffrey
AU - Mercer, Rebecca E.
AU - Dai, Wei Fang
AU - Beca, Jaclyn
AU - Tadrous, Mina
AU - Isaranuwatchai, Wanrudee
PY - 2020/1/7
Y1 - 2020/1/7
N2 - Background Oncology therapy is becoming increasingly more expensive and challenging the affordability and sustainability of drug programmes around the world. When new drugs are evaluated, health technology assessment organisations rely on clinical trials to inform funding decisions. However, clinical trials are not able to assess overall survival and generalises evidence in a real-world setting. As a result, policy makers have little information on whether drug funding decisions based on clinical trials ultimately yield the outcomes and value for money that might be expected. Objective The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, consisting of researchers, recommendation-makers, decision makers, payers, patients and caregivers, are developing and testing a framework for Canadian provinces to generate and use real-world evidence (RWE) for cancer drug funding in a consistent and integrated manner. Strategy The CanREValue collaboration has established five formal working groups (WGs) to focus on specific processes in the generation and use of RWE for cancer drug funding decisions in Canada. The different RWE WGs are: (1) Planning and Drug Selection; (2) Methods; (3) Data; (4) Reassessment and Uptake; (5) Engagement. These WGs are acting collaboratively to develop a framework for RWE evaluation, validate the framework through the multiprovince RWE projects and help to integrate the final RWE framework into the Canadian healthcare system. Outcomes The framework will enable the reassessment of cancer drugs, refinement of funding recommendations and use of novel funding mechanisms by decision-makers/payers across Canada to ensure the healthcare system is providing clinical benefits and value for money.
AB - Background Oncology therapy is becoming increasingly more expensive and challenging the affordability and sustainability of drug programmes around the world. When new drugs are evaluated, health technology assessment organisations rely on clinical trials to inform funding decisions. However, clinical trials are not able to assess overall survival and generalises evidence in a real-world setting. As a result, policy makers have little information on whether drug funding decisions based on clinical trials ultimately yield the outcomes and value for money that might be expected. Objective The Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration, consisting of researchers, recommendation-makers, decision makers, payers, patients and caregivers, are developing and testing a framework for Canadian provinces to generate and use real-world evidence (RWE) for cancer drug funding in a consistent and integrated manner. Strategy The CanREValue collaboration has established five formal working groups (WGs) to focus on specific processes in the generation and use of RWE for cancer drug funding decisions in Canada. The different RWE WGs are: (1) Planning and Drug Selection; (2) Methods; (3) Data; (4) Reassessment and Uptake; (5) Engagement. These WGs are acting collaboratively to develop a framework for RWE evaluation, validate the framework through the multiprovince RWE projects and help to integrate the final RWE framework into the Canadian healthcare system. Outcomes The framework will enable the reassessment of cancer drugs, refinement of funding recommendations and use of novel funding mechanisms by decision-makers/payers across Canada to ensure the healthcare system is providing clinical benefits and value for money.
KW - drug approval
KW - health technology assessment
KW - oncology
KW - real-world data
KW - real-world evidence
KW - regulatory approval
UR - http://www.scopus.com/inward/record.url?scp=85077721640&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077721640&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2019-032884
DO - 10.1136/bmjopen-2019-032884
M3 - Article
C2 - 31915169
AN - SCOPUS:85077721640
VL - 10
JO - BMJ Open
JF - BMJ Open
SN - 2044-6055
IS - 1
M1 - e032884
ER -